Co-Suspension Aerosphere Technology Enabling the Pharmaceutical Transition to Non-HFA Pressurized Metered Dose Inhalers With Reduced Environmental Impact
Lechuga-Ballesteros D, Lachacz K, Archbell J, Kassam I, Sommerville M, Riebe M, Joshi V.
Respiratory Drug Delivery 2023. Volume , 2023: 93-100.
Abstract:
Propellant replacement in pressurized metered dose inhalers (pMDIs) is not trivial, as demonstrated by the industry-wide experience of transitioning chlorofluorocarbon (CFC) propellants, necessitated by their ozone-depleting properties, with hydrofluoroalkane (HFA) propellants three decades ago. Today, HFAs are being replaced due to their high global warming potential (GWP), and the pharmaceutical industry is taking steps to transition to alternative low GWP propellants. Although formulation challenges are expected, this article describes the utilization of the Aerosphere® co-suspension platform, to facilitate the successful development of a next generation near-zero carbon triple combination pMDI.
I have a subscription
Log in for instant access.
I do not have a subscription
Purchase Article (in PDF format)
